Intravenous iron treatment of renal anemia in children on hemodialysis.
Treatment of anemia in children with end-stage renal disease (ESRD) has been greatly facilitated by the introduction of recombinant human erythropoietin (rHuEPO). A major limiting factor in the treatment of renal anemia is sufficient iron supplementation. Eight children (aged 10-17 years) receiving hemodialysis were treated with intravenous iron (1 mg/kg per week) for 3 months. Hemoglobin (Hb), hematocrit (Hct), and serum ferritin levels were measured regularly. The mean Hct increased from 25% to 30%, the mean Hb increased from 7. 8 g/dl to 9.2 g/dl, and the mean ferritin level from 200 to 395 mg/dl. The mean EPO dosage could be tapered from 6,500 IU to 6,150 IU. No adverse side-effects were noted. Hence, in this uncontrolled study intravenous iron was an effective treatment for iron deficiency during rHuEPO therapy in children with ESRD on hemodialysis.
Tenbrock
K
K
University Children's Hospital, Lindenthal, D-50924 Cologne, Germany,
Müller-Berghaus
J
J
Michalk
D
D
Querfeld
U
U
D000293:Adolescent; D000740:Anemia / Q000097:blood / Q000188:drug therapy*; D002648:Child; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D012079:Renal Circulation / Q000187:drug effects*; D006435:Renal Dialysis
D011994:Recombinant Proteins; D004921:Erythropoietin; D005293:Ferritins; D007501:Iron